Frequently Asked Questions
The market is segmented based on , By Drug Class (Factor Xa Inhibitor, Heparin, P2Y12 Platelet Inhibitor, and Other), Disease Type (Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis, and Other), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Route of Administration (Oral and Parenteral) – Industry Trends and Forecast to 2031.
.
The Global Thrombosis Drug Market size was valued at USD 11.24 USD Billion in 2023.
The Global Thrombosis Drug Market is projected to grow at a CAGR of 8.59% during the forecast period of 2024 to 2031.
The major players operating in the market include AstraZeneca (U.K.), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Sanofi (France), Aspen Holdings (South Africa), Bayer AG (Germany), Bristol Myers Squibb (U.S.), Pfizer Inc. (U.S.), Baxter (U.S.), GSK plc (U.K.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Grifols, S.A. (Spain), Viatris Inc. (U.S.), Biogen (U.S.), Vasudha Pharma (India), GoodRx, Inc. (U.S.), and ITALFARMACO S.p.A. (Italy).
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
